Birgit Voigt, Dirk Albrecht and Axel Dalhoff
Background: MCB3681, a novel quinolonyl-oxazolidinone antibacterial, is active against quinolone- and/or linezolidresistant Gram-positive bacteria. Thus, MCB3681 may interact with other targets than quinolones and oxazolidinones.
Methods and Findings: Protein expression in S. aureus following short-term exposure to MCB3681 was analyzed using 2D-gel electrophoresis and MALDI-TOF-MS/MS. Synthesis of 13 and 16 proteins was induced or repressed, respectively. Among the induced proteins are four ribosomal proteins. Repressed are proteins from different amino acid synthesis pathways, two aminoacyl-tRNAsynthetases, and methicillin-resistance-factor-protein FemB.
Conclusion: Our findings demonstrate that the impact of MCB3681 on the proteome signature of treated S. aureus cells is different from that of either ciprofloxacin or linezolid.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu